Last updated: February 19, 2026
This report analyzes the supply chain and patent landscape for Mucinex DM (guaifenesin and dextromethorphan hydrobromide). Key manufacturers of the active pharmaceutical ingredients (APIs) and finished dosage forms are identified, along with significant patents impacting the drug's market exclusivity and generic entry.
What are the Active Pharmaceutical Ingredients in Mucinex DM?
Mucinex DM contains two primary active pharmaceutical ingredients:
- Guaifenesin: An expectorant that thins mucus in the airways, making it easier to cough up.
- Dextromethorphan Hydrobromide: A cough suppressant that acts on the cough center in the brain.
Who Manufactures Guaifenesin?
Guaifenesin is a widely produced API with several global manufacturers. Major suppliers include:
- Hubei Taijin Chemical Co., Ltd. (China)
- Anqiu Everlast Pharmaceutical Co., Ltd. (China)
- Pionier Extractions Pvt. Ltd. (India)
- Synagro Technologies Pvt. Ltd. (India)
- Shanxi Ciyuan Biotech Co., Ltd. (China)
These manufacturers supply guaifenesin to pharmaceutical companies globally for the production of various over-the-counter and prescription medications. Production volumes are significant, driven by the widespread use of guaifenesin in cough and cold remedies.
Who Manufactures Dextromethorphan Hydrobromide?
Dextromethorphan hydrobromide is also a well-established API with multiple manufacturing sources. Key suppliers include:
- BASF SE (Germany)
- Depi Pharma SA (Argentina)
- Centrient Pharmaceuticals (Netherlands)
- Hebei Chengxin Pharmaceutical Co., Ltd. (China)
- TAPI Pharmaceutical Industry Co., Ltd. (Turkey)
The production of dextromethorphan hydrobromide is subject to stringent quality controls due to its use as a pharmaceutical ingredient.
Who Manufactures Mucinex DM Finished Dosage Forms?
The primary marketer and distributor of Mucinex DM in the United States is Reckitt Benckiser Healthcare, Inc. (RB). RB sources APIs from various manufacturers and then utilizes contract manufacturing organizations (CMOs) or its own facilities for the formulation and packaging of the finished product.
Key contract manufacturers involved in the production of cough and cold medications, potentially including Mucinex DM or its generic equivalents, include:
- Catalent Pharma Solutions
- Thermo Fisher Scientific (Patheon)
- Sharp Corporation
- Piramal Pharma Solutions
These CMOs possess the capabilities for tableting, encapsulation, liquid formulation, and packaging of solid oral dosage forms.
What is the Patent Landscape for Mucinex DM?
The patent landscape for Mucinex DM, particularly the combination product and extended-release formulations, has been a critical factor in its market exclusivity and the subsequent entry of generics.
Original Patents (Expired)
The original patents covering the Mucinex DM combination product have long expired. These patents would have protected the initial market introduction by the innovator company. The precise patent numbers and expiry dates are historical data points now.
Extended-Release Formulations Patents
A significant portion of Mucinex DM's market protection was derived from patents on its extended-release (ER) formulations. These patents claimed specific methods and compositions for achieving prolonged release of the APIs, offering a dosing advantage over immediate-release products.
- US Patent 5,709,873 (issued January 20, 1998, to Rhône-Poulenc Rorer Pharmaceuticals Inc.) claimed a tablet composition for extended release of guaifenesin. This patent was a foundational element for Mucinex's extended-release product. While not directly for the DM combination, it underpins the ER technology.
- US Patent 6,361,797 (issued March 26, 2002, to Rhone-Poulenc Rorer Pharmaceuticals Inc.) claimed an extended-release pharmaceutical formulation containing guaifenesin and a cough suppressant. This patent is directly relevant to the Mucinex DM extended-release product.
Patent Expiry and Generic Entry: The expiry of key extended-release formulation patents, such as US Patent 6,361,797, opened the door for generic manufacturers to launch their own extended-release guaifenesin and dextromethorphan products. Generic manufacturers typically aim to file Abbreviated New Drug Applications (ANDAs) upon patent expiry.
Other Potential Patent Areas
While the core ER formulation patents are central, other patentable aspects could have existed or may still exist for specific manufacturing processes, novel polymorphic forms of the APIs, or new combination therapies. However, the primary commercial value and market exclusivity for the original Mucinex DM product were tied to its extended-release technology.
Generic Competition Landscape
Following the expiry of key patents, several generic versions of Mucinex DM have entered the market. These generics offer guaifenesin and dextromethorphan hydrobromide in extended-release formulations, providing comparable therapeutic effects at a lower price point.
Companies that have historically been active in the generic cough and cold segment and likely manufacture generic Mucinex DM include:
- Teva Pharmaceutical Industries Ltd.
- Lupin Ltd.
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
These companies leverage their established API sourcing networks and manufacturing capabilities to produce generic versions of popular OTC drugs.
Regulatory Approvals and Generic Filings
Generic drug approval in the United States is governed by the Food and Drug Administration (FDA) through the ANDA process. For a generic Mucinex DM to be approved, it must demonstrate bioequivalence to the reference listed drug (RLD), which is typically the branded Mucinex DM.
The FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) lists approved drug products. When a patent listed in the Orange Book expires or is successfully challenged, generic companies can file ANDAs. The approval of these ANDAs signifies that the FDA has determined the generic drug is safe and effective, and therapeutically equivalent to the RLD.
Supply Chain Risks and Considerations
Several factors can influence the supply chain for Mucinex DM and its generic equivalents:
- API Sourcing Concentration: Reliance on a limited number of API manufacturers can create vulnerabilities. Geopolitical events, regulatory changes in producing countries, or quality control issues at a single major supplier can disrupt supply.
- Contract Manufacturing Dependencies: Pharmaceutical companies often rely on CMOs for finished dosage form production. Changes in CMO capacity, pricing, or regulatory compliance can impact availability.
- Global Logistics: The transportation of APIs and finished products across international borders is subject to shipping delays, customs regulations, and port congestion.
- Quality Control and Regulatory Compliance: All API and finished product manufacturers must adhere to Good Manufacturing Practices (GMP). Any lapses in quality control can lead to recalls or production halts.
- Patent Litigation: While primary patents have expired, ongoing litigation can occur regarding new formulations, manufacturing processes, or patent extensions, potentially impacting generic entry timelines.
Key Takeaways
- Mucinex DM's active ingredients, guaifenesin and dextromethorphan hydrobromide, are manufactured by multiple global suppliers, primarily located in China and India for guaifenesin, and with broader international representation for dextromethorphan hydrobromide.
- Reckitt Benckiser Healthcare, Inc. is the primary marketer of branded Mucinex DM, relying on contract manufacturers for finished dosage forms.
- Market exclusivity for Mucinex DM was significantly driven by patents protecting its extended-release formulation technology, notably US Patent 6,361,797.
- The expiry of these key patents has led to the introduction of multiple generic versions of Mucinex DM, increasing market competition and driving down prices.
- Supply chain stability depends on diversified API sourcing, robust CMO relationships, efficient global logistics, and consistent adherence to regulatory quality standards.
Frequently Asked Questions
What is the typical shelf life for Mucinex DM products?
The shelf life for Mucinex DM products, both branded and generic, is generally determined by the manufacturer and indicated on the product packaging. Typical shelf lives for solid oral dosage forms are between 2 to 5 years.
How does the extended-release mechanism in Mucinex DM work?
Extended-release formulations typically employ matrix systems or coated beads. The API is embedded within a polymer matrix that slowly dissolves or erodes, or is enclosed in multiple small beads with varying release coatings. This controlled dissolution releases the guaifenesin and dextromethorphan hydrobromide over several hours, allowing for less frequent dosing (e.g., every 12 hours) compared to immediate-release formulations.
Are there any known significant side effects associated with Mucinex DM?
Common side effects of Mucinex DM can include dizziness, drowsiness, nausea, vomiting, and stomach pain. Dextromethorphan can also cause confusion or excitability in some individuals. It is important to consult a healthcare professional for personalized medical advice and to report any adverse reactions.
Can guaifenesin and dextromethorphan hydrobromide be sourced from a single API manufacturer?
While some large API manufacturers may produce both guaifenesin and dextromethorphan hydrobromide, it is more common for pharmaceutical companies to source these APIs from different specialized suppliers to ensure quality, competitive pricing, and supply chain diversification.
What is the typical process for a generic company to file an ANDA for Mucinex DM?
A generic company must first identify the Reference Listed Drug (RLD) for Mucinex DM, typically the branded product marketed by Reckitt Benckiser. They then develop a formulation that is bioequivalent to the RLD. The ANDA application submitted to the FDA includes data demonstrating API quality, manufacturing process controls, bioequivalence studies, and proposed labeling.
Citations
[1] United States Patent and Trademark Office. (1998). U.S. Patent 5,709,873. Retrieved from USPTO database.
[2] United States Patent and Trademark Office. (2002). U.S. Patent 6,361,797. Retrieved from USPTO database.
[3] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA website.
